Characteristics of endovascular therapy
restenosis
RESTENOSIS
Table Characteristics of the target lesions and endovascular therapy. Data were compared using Chi-square test, t-test or Fisher's exact test. * percentages calculated from patients with stent insertion. † percentage calculated from patients with balloon angioplasty. BMS, bare metal stent; BTK, below-the-knee; DCB, drug-coated balloon; DES, drug-eluting stent; EVT, endovascular therapy; FP, femoropopliteal; SD, standard deviation; TASC, trans-atlantic inter-society consensus.The primary outcome of target lesion restenosis at 6 months was found in 19.1% (21/110) of the clopidogrel group and in 13% (13/100) of the sarpogrelate group (absolute risk difference 6.1%, 95% CI − 4.7 − 16.9% by Wald test with continuity correction). The non-inferiority of sarpogrelate compared to the clopidogrel was established, as the lower limit of the 95% CI was within the predefined margin of 0.05 (p-value for non-inferiority, 0.02; Fig. Noninferiority test for the primary outcome of target lesion restenosis.Prespecified subgroup analysis revealed that risk of target lesion restenosis between the two intervention arms was similar across most major subgroups (Fig. Subgroup analysis for the risk of target lesion restenosis.